FINWIRES · TerminalLIVE
FINWIRES

Palantir Expected to Deliver Robust Q1, Led by Growing Demand for AIP, Wedbush Says

By

-- Palantir (PLTR) is expected to deliver a robust Q1, led by the growing use-cases for its artificial intelligence platform as demand accelerates across both government and commercial fronts, Wedbush Securities said Wednesday, adding that PLTR remains on the Ives AI 30 list.

Wedbush believes Palantir has the potential to reach a trillion-dollar market cap in the next few years as the AI Revolution unfolds.

The Street's top-line estimate of $1.54 billion seems beatable, as US commercial revenue is expected to grow beyond the 139% growth seen in Q4, supported by AIP and the Street underestimating Palantir's commercial efforts, the brokerage said.

Wedbush said Palantir's Q1 bottom-line expectation of $870 million to $874 million seems achievable, despite significant investments into the product pipeline, elite technical hiring and AIP.

Palantir has also signed several 9-figure contracts with multiple federal government agencies, pointing to increased adoption of its tech across the government landscape, according to the note.

The company is set to report Q1 results on Monday after the bell.

Wedbush maintained an outperform rating on Palantir with a $230 price target.

Price: $136.81, Change: $-4.37, Percent Change: -3.10%

Related Articles

Australia

Mizuho Securities Raises Price Target on Apellis Pharmaceuticals to $41 From $20, Maintains Neutral Rating

Apellis Pharmaceuticals (APLS) has an average rating of hold and mean price target of $40.82, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $40.95, Change: $-0.05, Percent Change: -0.11%

$APLS
Research

Mizuho Securities Downgrades Terns Pharmaceuticals to Neutral From Outperform, Trims Price Target to $53 From $54

Terns Pharmaceuticals (TERN) has an average rating of hold and mean price target of $53, according to analysts polled by FactSet.

$TERN
Research

Research Alert: CFRA Reiterates Buy Opinion On Shares Of Booking Holdings Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month target price by $8 to $196, 19x our 2026 EPS estimate (unchanged) and a discount to its 23x five-year average forward multiple, reflecting geopolitical risks. We lower our 2026 EPS to $10.33 from $10.74 and 2027's to $11.58 from $12.07, primarily reflecting lower gross bookings growth from the Middle East conflict. We maintain our Buy opinion as shares are undervalued given long-term competitive strengths and temporary geopolitical headwinds. The company's Connected Trip platform and Genius loyalty program are supporting higher-margin direct bookings, suggesting AI initiatives are strengthening consumer engagement rather than disintermediating the platform. Strong free cash flow supports future shareholder returns, including $3.6 billion in Q1 buybacks. While the Middle East conflict will impact Q2 bookings, BKNG has a history of seeing travel rebound following geopolitical or economic disruptions. U.S. room night growth accelerated in Q1 to a low-teens range, providing near-term momentum.

$BKNG